How this company measures up on the fundamentals that matter

Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa. The company offers sequencing- and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers, as well as through life-science distributors. The company has a collaboration with Labcorp Holdings Inc. for the development of oncology treatments through applications of sequencing solutions across the healthcare ecosystem. It also has a data partnership with Center for Data-Driven Discovery in Biomedicine to advance research in pediatric cancer and rare disease. Illumina, Inc. was incorporated in 1998 and is headquartered in San Diego, California.

https://www.illumina.com

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Trading at $142, 43% above fair value of $100. Fails ethical screen (Debt ratio 38.4%). Ranks better than 6% of screened stocks.

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Trading characteristics and market positioning

Balance sheet strength and cash generation — the foundation of long-term value

SEC Form 4 filings — what company insiders are buying and selling